Navigation Links
The Leukemia & Lymphoma Society Targets Research in Four Critical Areas of Unmet Medical Need

WHITE PLAINS, N.Y., Dec. 14, 2010 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is taking an aggressive approach to tackling the challenge of improving outcomes for patients with cancers that remain stubbornly resistant to treatment.  As it has for more than 62 years, LLS will continue to accept applications from the world's best and brightest scientists to advance progress in all areas of blood cancer, and award grants based on merit.  In addition LLS has identified four specific areas of need, and is soliciting applications from scientists and physicians who are working on these difficult problems.

"We are charting the course by identifying and prioritizing the areas of need and directing funding to research that shows the most promise for improving survival and quality of life for patients with these particular diseases," said Louis DeGennaro, Ph.D., LLS chief mission officer.  "LLS wants to deliver better treatments, faster, to patients, and we have developed an innovative, strategic approach to achieve this goal."

LLS is issuing requests for proposals (RFP) from researchers working in the following areas:

  • Identification and characterization of the leukemic stem cell in acute myeloid leukemia and myelodysplastic syndrome and the identification of potential targeted therapies
  • Novel therapeutic strategies for non-cutaneous T-cell lymphoproliferative disorders
  • Development of therapeutic strategies for the high risk myeloma patient
  • Mechanisms underlying long term and late effects resulting from cancer treatment and the development measures to significantly reduce or prevent these toxicities

  • Applications responsive to these RFPs should be submitted under LLS's Translational Research Program, a program designed to help accelerate the movement of promising discoveries from the lab to the clinic.  A detailed description of the LLS Translational Research Program and application instructions are available here.

    About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

    Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. Andrea Greif(914)

    SOURCE The Leukemia & Lymphoma Society
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
    2. Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
    3. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
    4. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
    5. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
    6. Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
    7. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
    8. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
    9. Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
    10. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
    11. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
    Post Your Comments:
    (Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
    (Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
    (Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
    (Date:11/30/2015)... ... November 30, 2015 , ... ... ingredient list of its hemorrhoid ointment to its website. , “Our goal is ... people suffering from hemorrhoids. Adding the comparison chart and ingredient list allows our ...
    (Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their priority is ... When you have dental problems, you need to turn to a dentist who listens ... treat your needs, a friendly dentist who counsels you on the best ways to ...
    (Date:11/30/2015)... ... ... Dr. Seth D. Margulies specializes in orthodontics and is based in Perth ... the best available orthodontic experience in the area. Dr. Margulies has met all ... the branch of dentistry that specializes in the diagnosis, prevention, and treatment of dental ...
    (Date:11/30/2015)... , ... November 30, 2015 , ... ... new study by UPMC and KingMed Diagnostics researchers. Their ... years found that consultation with UPMC pathologists resulted in significantly altered treatment plans ...
    Breaking Medicine News(10 mins):